ATE206041T1 - Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe - Google Patents

Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe

Info

Publication number
ATE206041T1
ATE206041T1 AT96925932T AT96925932T ATE206041T1 AT E206041 T1 ATE206041 T1 AT E206041T1 AT 96925932 T AT96925932 T AT 96925932T AT 96925932 T AT96925932 T AT 96925932T AT E206041 T1 ATE206041 T1 AT E206041T1
Authority
AT
Austria
Prior art keywords
block copolymer
polyether block
biological substances
targeted administration
micellar compositions
Prior art date
Application number
AT96925932T
Other languages
English (en)
Inventor
Alexander V Kabanov
Valery Yu Alakhov
Vladimir P Chekhonin
Elena V Batrakova
Victor A Kabanov
Original Assignee
Supratek Pharma Inc
Alexander V Kabanov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc, Alexander V Kabanov filed Critical Supratek Pharma Inc
Application granted granted Critical
Publication of ATE206041T1 publication Critical patent/ATE206041T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyethers (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96925932T 1995-06-07 1996-06-07 Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe ATE206041T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/478,979 US6153193A (en) 1993-04-28 1995-06-07 Compositions for targeting biological agents
PCT/IB1996/000801 WO1996040056A1 (en) 1995-06-07 1996-06-07 Polyether block copolymer micellar compositions for targeting biological agents

Publications (1)

Publication Number Publication Date
ATE206041T1 true ATE206041T1 (de) 2001-10-15

Family

ID=23902180

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96925932T ATE206041T1 (de) 1995-06-07 1996-06-07 Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe

Country Status (11)

Country Link
US (1) US6153193A (de)
EP (1) EP0839026B1 (de)
JP (1) JPH11507028A (de)
AT (1) ATE206041T1 (de)
AU (1) AU6628496A (de)
CA (1) CA2236946A1 (de)
DE (1) DE69615561T2 (de)
DK (1) DK0839026T3 (de)
ES (1) ES2163034T3 (de)
PT (1) PT839026E (de)
WO (1) WO1996040056A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5869539A (en) * 1996-04-17 1999-02-09 Board Of Regents, The University Of Texas System Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5948896A (en) * 1997-08-13 1999-09-07 Gem Pharmaceuticals Processes for preparing 13-deoxy anthracycline derivatives
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO2002085337A1 (en) * 2001-04-20 2002-10-31 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
CA2440935A1 (en) * 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
GB0120701D0 (en) 2001-08-24 2001-10-17 Maelor Pharmaceuticals Ltd Pharmaceutical formulations
FR2833268B1 (fr) * 2001-12-12 2005-07-08 Fabre Pierre Dermo Cosmetique Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2843117B1 (fr) 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
EP1393718A1 (de) * 2002-08-29 2004-03-03 OctoPlus Sciences B.V. Kolloidal Wirkstoffträgersystem
JP4970731B2 (ja) * 2002-12-04 2012-07-11 フラメル・テクノロジー 少なくとも１つの（オリゴ）アミノ酸基によって官能性をもたせたポリアミノ酸およびこれらの適用、特に医療適用
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
CA2547077C (en) * 2003-12-01 2015-11-03 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
FR2873704B1 (fr) * 2004-07-30 2006-12-08 Flamel Technologies Sa Polyaminoacides fonctionnalises par des greffons hydrophobes portant une charge anionique et leurs applications notamment therapeutiques
FR2873703B1 (fr) * 2004-07-30 2006-12-08 Flamel Technologies Sa Polyaminoacides branches, fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
TWI278615B (en) * 2004-12-29 2007-04-11 Ind Tech Res Inst Nano-micelle carrier using in near infrared image detection and detection method therewith
FR2881140B1 (fr) * 2005-01-27 2007-04-06 Flamel Technologies Sa Copolyhydroxyalkylglutamines fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2892725B1 (fr) * 2005-10-31 2011-03-04 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des derives de l'histidine et des groupements hydrophobes et leurs applications notamment therapeutiques
FR2915748B1 (fr) 2007-05-03 2012-10-19 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des groupes cationiques et des groupements hydrophobes et leurs applications, notamment therapeutiques
WO2010006192A1 (en) * 2008-07-09 2010-01-14 Board Of Regents Of The University Of Nebraska Functional micelles for hard tissue targeted delivery of chemicals
US20140296173A1 (en) * 2013-03-28 2014-10-02 Bbs Nanotechnology Llc. Stable nanocomposition comprising epirubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027013A (en) * 1976-01-22 1977-05-31 William L. Wilson Clottable fibrinogen free factor VIII and albumin product and process
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4865835A (en) * 1982-06-02 1989-09-12 Begent Richard H J Diagnosis and treatment of tumors
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4474752A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4957735A (en) * 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
JPS61103836A (ja) * 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
US5183687A (en) * 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
US5234683A (en) * 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US5494660A (en) * 1985-06-18 1996-02-27 Emory University Method for inhibiting microbial binding to surfaces
US5114708A (en) * 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US5466445A (en) * 1985-06-18 1995-11-14 Emory University Methods for reducing salmonella in chickens
DE3684333D1 (de) * 1985-06-18 1992-04-16 Univ Emory Biologisch wirksame kopolymere.
BR8603586A (pt) * 1985-07-30 1987-03-10 Int Minerals & Chem Corp Processo para manter a fluidez de um homonio;processo para efetuar a promocao de crescimento em animais e formulacao promotora de crescimento
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5240702A (en) * 1986-05-15 1993-08-31 Emory University Method of treating stroke
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5240701A (en) * 1986-05-15 1993-08-31 Emory University Method of performing angioplasty procedures
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5152979A (en) * 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US4882168A (en) * 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
JPH01501064A (ja) * 1986-09-22 1989-04-13 エモリ　ユニバーシティ ワクチンとその製法
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5567859A (en) * 1991-03-19 1996-10-22 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
AU1396588A (en) * 1987-02-20 1988-09-14 Emory University Antiinfective compounds and method of use
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
WO1989001159A1 (en) * 1987-07-27 1989-02-09 Commonwealth Scientific And Industrial Research Or Receptor membranes
US4853228A (en) * 1987-07-28 1989-08-01 Micro-Pak, Inc. Method of manufacturing unilamellar lipid vesicles
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
JPH0776175B2 (ja) * 1990-04-26 1995-08-16 サイトアーレクス・コーポレーシヨン 損傷されたかまたは病気になった組織の局所的処置用の組成物および方法
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
HUT67762A (en) * 1991-03-19 1995-04-28 Cytrx Corp Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5622649A (en) * 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
EP0643620B1 (de) * 1991-10-04 1999-07-21 Gs Development Ab Teilchen, methode zur herstellung der teilchen und deren verwendung
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
KR940003548U (ko) * 1992-08-14 1994-02-21 김형술 세탁물 건조기
AU5147193A (en) * 1992-10-08 1994-05-09 Valery Yu Alakhov Composition of antineoplastic agents incorporated in micelles
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US5840319A (en) * 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
DE69428521T2 (de) * 1993-02-02 2002-05-23 Xoma Technology Ltd Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
IL106578A (en) * 1993-08-03 2000-08-13 Yissum Res Dev Co Pharmaceutical compositions for drug targeting
JP3682475B2 (ja) * 1993-08-31 2005-08-10 靖久 桜井 水溶性抗癌剤
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5401296A (en) * 1994-06-28 1995-03-28 Martenson; Irvin Precious metal extraction process
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy

Also Published As

Publication number Publication date
DE69615561T2 (de) 2002-07-11
EP0839026A1 (de) 1998-05-06
CA2236946A1 (en) 1996-12-19
JPH11507028A (ja) 1999-06-22
DK0839026T3 (da) 2002-01-21
DE69615561D1 (de) 2001-10-31
EP0839026B1 (de) 2001-09-26
WO1996040056A1 (en) 1996-12-19
PT839026E (pt) 2002-01-30
AU6628496A (en) 1996-12-30
ES2163034T3 (es) 2002-01-16
US6153193A (en) 2000-11-28

Similar Documents

Publication Publication Date Title
ATE206041T1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
ATE337019T1 (de) Geladene lipide und deren verwendung
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE59905954D1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
GEP20053511B (en) ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase
DE69735581D1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
ATE213164T1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
DE69535576D1 (de) Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie
GEP20022804B (en) Erythropoietin Derivatives
ATE314067T1 (de) Cannabinol-11-säurederivate als entzündungshemmer und analgetika
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
BR9611571B1 (pt) composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal.
DE69724599D1 (de) Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung
ATE226094T1 (de) Verfahren zur arzneistoffabgabe mittels gentherapie
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
FI801228A (fi) 6-substituerade 11-alkylen-morfantridiner foerfaranden foer deras framstaellning och terapeutiska medel innehaollande dessa
ATE199641T1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ATE226065T1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee